ERK and P38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition Via Regulation of MYC and YAP

Overview

Journal Cancer Res

Specialty Oncology

Date 2016 Dec 4

PMID 27913436

Citations 36

Authors

Taru Muranen

Laura M Selfors

Julie Hwang

Lisa L Gallegos

Jonathan L Coloff

Carson C Thoreen

Seong A Kang

David M Sabatini

Gordon B Mills

Joan S Brugge

Affiliations

Soon will be listed here.

Abstract

Aberrant activation of the PI3K/mTOR pathway is a common feature of many cancers and an attractive target for therapy, but resistance inevitably evolves as is the case for any cancer cell-targeted therapy. In animal tumor models, chronic inhibition of PI3K/mTOR initially inhibits tumor growth, but over time, tumor cells escape inhibition. In this study, we identified a context-dependent mechanism of escape whereby tumor cells upregulated the proto-oncogene transcriptional regulators c-MYC and YAP1. This mechanism was dependent on both constitutive ERK activity as well as inhibition of the stress kinase p38. Inhibition of p38 relieved proliferation arrest and allowed upregulation of MYC and YAP through stabilization of CREB. These data provide new insights into cellular signaling mechanisms that influence resistance to PI3K/mTOR inhibitors. Furthermore, they suggest that therapies that inactivate YAP or MYC or augment p38 activity could enhance the efficacy of PI3K/mTOR inhibitors. Cancer Res; 76(24); 7168-80. ©2016 AACR.

Citing Articles

Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.

Park S, Ryu W, Kim T, Hwang Y, Han H, Lee J Exp Mol Med. 2024; 56(4):987-1000.

PMID: 38622197 PMC: 11059244. DOI: 10.1038/s12276-024-01210-5.

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.

Chen W, Park J Int J Mol Sci. 2023; 24(19).

PMID: 37834284 PMC: 10573597. DOI: 10.3390/ijms241914837.

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

Bhin J, Yemelyanenko J, Chao X, Klarenbeek S, Opdam M, Malka Y J Exp Med. 2023; 220(11).

PMID: 37642941 PMC: 10465700. DOI: 10.1084/jem.20211743.

Adjuvant therapy with Huatan Sanjie Granules improves the prognosis of patients with primary liver cancer: a cohort study and the investigation of its mechanism of action based on network pharmacology.

Yuan J, Abdurahman A, Cui N, Hao T, Zou J, Liu L Front Pharmacol. 2023; 14:1091177.

PMID: 37324453 PMC: 10267985. DOI: 10.3389/fphar.2023.1091177.

Assessing the epithelial-to-mesenchymal plasticity in a small cell lung carcinoma (SCLC) and lung fibroblasts co-culture model.

Dhungel N, Youngblood R, Chu M, Carroll J, Dragoi A Front Mol Biosci. 2023; 10:1096326.

PMID: 36936987 PMC: 10022497. DOI: 10.3389/fmolb.2023.1096326.

References

Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins J . Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000; 14(19):2501-14. PMC: 316970. DOI: 10.1101/gad.836800. View

Jo H, Jia Y, Subramanian K, Hattori H, Luo H . Cancer cell-derived clusterin modulates the phosphatidylinositol 3'-kinase-Akt pathway through attenuation of insulin-like growth factor 1 during serum deprivation. Mol Cell Biol. 2008; 28(13):4285-99. PMC: 2447147. DOI: 10.1128/MCB.01240-07. View

Diehl N, Enslen H, Fortner K, Merritt C, Stetson N, Charland C . Activation of the p38 mitogen-activated protein kinase pathway arrests cell cycle progression and differentiation of immature thymocytes in vivo. J Exp Med. 2000; 191(2):321-34. PMC: 2195760. DOI: 10.1084/jem.191.2.321. View

Tenbaum S, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S . β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med. 2012; 18(6):892-901. DOI: 10.1038/nm.2772. View

Samuels Y, Velculescu V . Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004; 3(10):1221-4. DOI: 10.4161/cc.3.10.1164. View

Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A . Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med. 2011; 17(9):1116-20. PMC: 3169724. DOI: 10.1038/nm.2402. View

Cannell I, Kong Y, Johnston S, Chen M, Collins H, Dobbyn H . p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci U S A. 2010; 107(12):5375-80. PMC: 2851793. DOI: 10.1073/pnas.0910015107. View

Coulthard L, White D, Jones D, McDermott M, Burchill S . p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009; 15(8):369-79. PMC: 3016890. DOI: 10.1016/j.molmed.2009.06.005. View

Balz L, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zanker K . The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination. J Pathol. 2012; 227(2):234-44. DOI: 10.1002/path.3991. View

10.

Zhang T, Zhang J, You X, Liu Q, DU Y, Gao Y . Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology. 2012; 56(6):2051-9. DOI: 10.1002/hep.25899. View

11.

Cope C, Gilley R, Balmanno K, Sale M, Howarth K, Hampson M . Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J Cell Sci. 2013; 127(Pt 4):788-800. DOI: 10.1242/jcs.137588. View

12.

Ilic N, Utermark T, Widlund H, Roberts T . PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A. 2011; 108(37):E699-708. PMC: 3174675. DOI: 10.1073/pnas.1108237108. View

13.

Wang J, Park J, Wei Y, Rajurkar M, Cotton J, Fan Q . TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function. Mol Cell. 2013; 51(2):211-25. PMC: 4007693. DOI: 10.1016/j.molcel.2013.05.013. View

14.

Sutherlin D, Sampath D, Berry M, Castanedo G, Chang Z, Chuckowree I . Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem. 2010; 53(3):1086-97. DOI: 10.1021/jm901284w. View

15.

Schewe D, Aguirre-Ghiso J . ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci U S A. 2008; 105(30):10519-24. PMC: 2492459. DOI: 10.1073/pnas.0800939105. View

16.

Deak M, Clifton A, Lucocq L, Alessi D . Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 1998; 17(15):4426-41. PMC: 1170775. DOI: 10.1093/emboj/17.15.4426. View

17.

Serra V, Eichhorn P, Garcia-Garcia C, Ibrahim Y, Prudkin L, Sanchez G . RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013; 123(6):2551-63. PMC: 3668839. DOI: 10.1172/JCI66343. View

18.

Kim M, Kim J, Hong H, Lee S, Lee J, Jung E . Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J. 2015; 35(5):462-78. PMC: 4772854. DOI: 10.15252/embj.201592081. View

19.

Abravanel D, Belka G, Pan T, Pant D, Collins M, Sterner C . Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest. 2015; 125(6):2484-96. PMC: 4497740. DOI: 10.1172/JCI74883. View

20.

Lin L, Sabnis A, Chan E, Olivas V, Cade L, Pazarentzos E . The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015; 47(3):250-6. PMC: 4930244. DOI: 10.1038/ng.3218. View